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CHAPTER ONE

INTRODUCTION

1.1 Background
Fungal infections have become more prevalent in the past 50 years and continue
to be a significant threat to worldwide health. Surveying public health authorities have
generally neglected to gather statistics on pathogenic fungi, as they are rarely
communicable, unlike bacteria and viruses (Casadevall 2018). Despite the limited data,
fungal infections are found to affect over one billion people and cause over 1.5 million
deaths annually, similar to that of tuberculosis and far surpassing the malaria death toll
(Casadevall 2018; Brown et al. 2012). Out of an estimated 2.2 to 3.8 million fungal
species, approximately three hundred are known to be pathogenic to humans
(Hawksworth and Lücking 2017; Taylor, Latham, and Woolhouse 2001). The majority
of deaths caused by fungal infections are attributed to three fungi genera: Aspergillus,
Candida, and Cryptococcus (Brown et al. 2012). Despite existing antifungal therapies
used to combat these organisms, the global burden of invasive fungal diseases still
remains high, thus calling for the urgent need of new and effective antifungals.
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1.2 Antifungal Therapeutics
Antifungals currently used to treat fungal infections are commonly divided into
the following four main classes according to their mechanisms of action: cell membrane
disruptors (polyenes), ergosterol biosynthesis inhibitors (azoles and allylamines), glucan
synthesis inhibitors (echinocandins), and DNA/RNA synthesis inhibitors (flucytosine)
(Boyce et al. 2019; Cowen et al. 2014). A summary of these mechanisms is shown in
Figure 1.1.

Echinocandins

Azoles

Polyenes

Allylamines

Cell Wall

Membrane

Ergosterol

Lanosterol

Squalene

Figure 1.1 A schematic of the current classes of antifungals (excluding flucytosine)
and their mechanisms of action. The schematic includes the fungal cell wall and
plasma membrane with cell wall components indicated by the following: chitin
(blue), ß-glucans (light green, dark green, and red), proteins (yellow), and mannans
(orange) (Adapted from Brown et al. 2012 and Boyce et al. 2019).
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Polyenes, specifically amphotericin b (AmpB), have been clinically used since the
1950s to inhibit Aspergillus, Candida, and Cryptococcus by intercalating with ergosterol
in the fungal cell membrane. This action induces the formation of membrane spanning
pores allowing the leakage of cellular components thus resulting in the disruption of vital
cellular functions (Robbins, Caplan, and Cowen 2017). AmpB has been the standard
drug used to treat systemic fungal infections because of its potent broad-spectrum
activity. However, AmpB has shown nephrotoxicity as a common side effect which has
led it to being administered in low doses and in combination with other antifungals to
reduce its toxicity (Keele et al. 2002).
Azoles (e.g. fluconazole, itraconazole, etc.) inhibit the lanosterol 14-αdemethylase enzyme encoded by cyp51 in Aspergillus niger and ERG11 in both Candida
albicans and Cryptococcus neoformans preventing the conversion of lanosterol to
ergosterol, an essential component of the fungal cell membrane (Shapiro, Robbins, and
Cowen 2011). Like azoles, allylamines, such as terbinafine, halt the synthesis of
ergosterol but do so by inhibiting squalene epoxidase, the enzyme responsible for the
conversion of squalene to lanosterol, the precursor of ergosterol (Boyce et al. 2019).
However, due to the interaction between azoles and cytochrome P450 enzymes, these
drugs are not suitable for individuals undergoing multidrug therapy (Srivinivasan, LopezRibot, and Ramasubramanian 2014; Lynch and Price 2007)
Echinocandins including micafungin, caspofungin, and anidulafungin prevent the
synthesis of 1,3-ß-glucan, a critical cell wall biopolymer, by noncompetitively inhibiting
1,3-ß-glucan synthase encoded by FSK1/2 (Denning 2003). As a result, the fungal cell
wall destabilizes causing osmotic stress and cell lysis (Matejuk et al. 2010). Despite
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these large lipopeptides showing potent antifungal efficacy against most Candida species
and some Aspergillus, this class of antifungals display no activity against Cryptococcus.
Also, echinocandins have been found to poorly absorb by oral administration (Denning
2003).
Lastly, one of the oldest antifungal agents, 5-fluorocytosine, more well known as
flucytosine, is a pyrimidine analog proven to be active against Candida and Cryptococcus
species. As fungal cells uptake flucytosine, it is quickly deaminated into 5-fluorouricil
which metabolizes into 5-fluorodeoxyuridine monophosphate, an inhibitor of thymidylate
synthase which is a crucial enzyme in DNA synthesis. Another proposed mechanism is
the metabolism of flucytosine into 5-fluorouridine triphosphate which replaces uridine
monophosphate in fungal RNA therefore inhibiting RNA synthesis (Vermes, Guchelaara,
and Dankert 2000). Similar to AmpB, flucytosine presents undesirable side effects which
include myelosuppression and gastrointestinal disturbance (Bicanic and Harrison 2004).
Since the addition of echinocandins to the antifungal pipeline in the early 2000s,
no new class of antifungals has reached the clinic (Perfect 2017). Consequently, these
four classes have been employed as the primary treatment options for fungal infections
over the last two decades. Because of the lack of diversity of chemical structure and
mechanism of action among the current treatments and their widespread use, antifungal
resistance has emerged in every class (Gamaletsou, Walsh, and Sipsas 2018; Cowen
2008; Perea and Patterson 2002). With the limitations of each drug class and antifungal
resistance on the rise, the development of new antifungal agents is necessary.
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1.3 Cryptococcus
Cryptococcus is one of the leading contributors to fungal infections and fungal
related deaths in the world. Out of the 37 species of Cryptococcus, the two most
common pathogenic species are Cryptococcus neoformans and Cryptococcus gattii
(Cheng et al. 2001; Srinkata, Santiago-Tirado, and Doering 2014). C. neoformans has
been classified as a species complex comprised of four distinct serotypes, A, B, C, and D.
C. neoformans var grubii and C. neoformans var neoformans are recognized as serotypes
A and D, respectively, while C. neoformans var gattii is considered as serotypes B and C
(Springer and Chaturvedi 2010). However, because of morphological, ecological, and
genomic differences, C. gattii is now recognized as a separate species from C.
neoformans (Kwon-Chung et al. 2002).
C. neoformans is ubiquitous in soil and bird excrement, while C. gatii has
generally been found in tropical and subtropical regions and more recently in the Pacific
Northwest (Bicanic and Harrison 2004; Datta et al. 2009). Additionally, both species
have been located in the hollows of decaying trees in South America (Lazéra et al. 1996).
These two fungal species are the primary cause for cryptococcosis (cryptococcal
infections). Cryptococcal infections mainly occur due to inhalation of cryptococcal
basidiospores from the environment. Once inhaled, the fungal cells move deep into the
lungs resulting in a pulmonary infection or spread throughout the body to the central
nervous system causing meningitis and/or meningoencephalitis which is fatal if left
untreated (Gibson and Johnston 2015; Bovers, Hagen, and Boekhout 2008).
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Cryptococcal infections due to C. neoformans are predominantly found in
immunocompromised individuals such as human immunodeficiency virus or acquired
immunodeficiency syndrome (HIV/AIDS) patients, organ transplant recipients, and
patients undergoing chemotherapy, while C. gattii has been found to mainly infect
immunocompetent hosts (Pappas 2013; Chen, Meyer, and Sorrell 2014). Nevertheless,
there has been evidence of C. neoformans infecting immunocompetent individuals as
well (Panackal et al. 2015). Cryptococcosis is especially of great concern in low income
countries and regions with a high prevalence of HIV/AIDS, such as sub-Saharan Africa,
as cryptococcal meningitis is the second most common cause of AIDS related fatalities
after tuberculosis (Hurtado et al. 2019; Rajasingham et al. 2017). In most recent studies,
it is estimated 220,000 cases of cryptococcal meningitis occur each year among
individuals with HIV/AIDS worldwide with 181,000 of those resulting in death, an
approximate 80 % mortality rate (Rajasingham et al. 2017).
C. neoformans’ pathogenicity and ability to survive its host’s immunogenic
response are largely attributed to its unique virulence factors. Like other fungal yeasts,
C. neoformans possesses a plasma membrane and a cell wall composed of glucans, chitin,
and glycoproteins, but it is one of the few pathogenic fungi which exhibit a
polysaccharide capsule (Figure 1.2). Composed primarily of glucuronoxylomannan
(GXM) and galactoxylomannan (GalXM), the capsule functions as the fungi’s main
virulence factor by allowing cryptococcal cells to evade death by phagocytosis (Zaragoza
et al. 2009). The production of the pigment melanin by the cell wall protein laccase also
protects C. neoformans against macrophages by scavenging reactive oxygen species
employed by the host defense system (Rodrigues, Alviano, and Travassos 1999).
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Because the capsule is anchored to the fungal cell wall through α-1,3-glucan, cell wall
integrity plays an important role in C. neoformans’ virulence. Studies have shown the
disruption of the cell wall through mutation of α-1,3-glucan synthase not only made
cryptococcal cells more sensitive to stress conditions but also attenuated virulence (Reese
et al. 2007). The cell wall component chitin, a linear polymer of α -(1,4)-linked Nacetylglucosamine (GlcNAc), and its deacylated form, chitosan, heavily contribute to cell
wall strength and structural integrity. C. neoformans chitosan knockouts have been
shown to both induce cell wall leaking of melanin and affect capsule size making
cryptococcal cells more susceptible to death by the host’s defenses (Baker et al. 2007;
Baker, Specht, and Lodge 2011).

Figure 1.2 Light microscope image of India ink stained encapsulated Cryptococcus
neoformans strain 24067 serotype D at 100x magnification. This image is courtesy of
Marjan Berenji Jalai.
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The preferred therapies for treatment against cryptococcosis are AmpB,
fluconazole, and flucytosine. Some C. neoformans strains have been reported to be
resistant to each of these antifungal agents (Coelho and Casadevall 2016). Acquired
resistance to AmpB has been associated with a point mutation in the ERG2 gene
encoding for 8-7 sterol isomerase enzyme (Kelly et al. 1994). For the majority of azoles,
a subpopulation of most C. neoformans isolates are intrinsically resistant (heteroresistant)
actually benefiting their fungistatic nature. However, resistance to fluconazole is
inevitable as long-term monotherapy of this agent is the common choice of treatment for
those in low income countries with limited or no access to flucytosine (Lamb et al. 1995;
Smith et al. 2015; Rajasingham et al. 2012). In regard to flucytosine, secondary
resistance is so common it cannot singly be used to treat cryptococcosis (Loyse et al.
2013; Coelho and Casadevall 2016). Resistance to these agents along with their
deleterious side effects are evidence that the development of new anti-cryptococcal
treatments is imperative.

1.4 Antifungal Peptides
Natural peptides have been of growing interest in the development of safe and
effective antifungal therapies as many are not toxic to mammalian cells.
Echinocandins, the newest class of antifungal drugs, are currently the only approved
group of antifungal peptides (AFPs) by the Food and Drug Administration (FDA);
however, these peptides have a small range of activity excluding C. neoformans (Matejuk
et al. 2010). Nevertheless, there are many AFPs still being identified for their anticryptococcal activity and hold potential in anti-cryptococcal development.
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AFPs are commonly found in animals, bacteria, fungi, and plants and are usually
classified into two groups by their mechanism of action. The first group are
predominantly amphipathic peptides that lyse fungal cells by disrupting the cell
membrane. The second group of AFPs act by hindering cell wall synthesis or the
biosynthesis of essential cellular components such as chitin and glucan (De Lucca and
Walsh 1999). The first class of AFPs has been found to be more effective against C.
neoformans than the second. Examples of these include defensins, syringomycins,
histatins, and cathelicidins (Matejuk et al. 2010). Though highly studied for their
candidacidal activities, derived peptides of iron-binding glycoprotein, lactoferrin, have
also been shown to be active against C. neoformans (Kondori et al. 2011). It is proposed
lactoferrins kill fungi by altering cell membrane permeability through sequestration of
iron (Fernandes and Carter 2017).
While the continual study of AFPs is rapidly moving antifungal development
forward, there are still certain challenges in using these peptides as drugs. One of the
greatest obstacles is that AFPs have low stability and can be proteolytically degraded in
serum. To overcome this problem, approaches using recombinant technologies and
protein engineering have been implemented to increase peptide stability (Knappe et al.
2010; Faruck, Yusof, and Chowdhury 2016). One such example is when Tati et al.
constructed a conjugate peptide by linking the active fragment of histatin 5 (Hst54-15) to
spermidine (Spd) to combat Candida biofilm formation, a phenotypic resistance
mechanism of many fungi (Tati et al. 2014; Delattin et al. 2017). This alteration not only
led to a greater clinical half-life but also increased candidacidal activity even better than
the native Hst5 (Tati et al. 2014).
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1.5 Lectins as Antimicrobial Agents
Lectins are a class of proteins that recognize and bind carbohydrate complexes in
lipids or proteins in a highly specific and reversible manner. This capability allows them
to interact with glycans of cell surface glycoconjugates. Because glycans can be
expressed with endless carbohydrate arrangements across cell types, lectins are excellent
candidates for drug targeting systems with high specificity. Such a system could utilize a
lectin as a target moiety to deliver an antimicrobial drug to a specific glycolipid or
glycoprotein on the cell surface of a pathogenic microbe (Ximenes et al. 2015; Bies,
Lehr, and Woodley 2004; Lavín de Juan et al. 2017).
Numerous plant lectins have been found to naturally show antimicrobial activity.
Several of these lectins bind N-linked high mannose glycans on viral envelope
glycoproteins such as gp120 and gp41on the surface of HIV (Lagarda-Diaz, GuzmanPartida, and Vazquez-Moreno 2017). These glycoproteins are necessary to facilitate
virus entry into cells and play a critical role in the interaction with CD4 cell surface
receptors (Wyatt et al. 1998). Therefore, drugs that bind to these mannose moieties can
inhibit viral transmission into the host. Lectins that have been shown to inhibit HIV in
this way include Cyanovirin (CV-N), Microvirin (MVN), Scytovirin (SVN), and
Griffithsin (GRFT) (Soares Gomes et al. 2018). Though high mannose binding lectins
have long been studied for their antiviral properties, Scytovirin, has been of primary
interest for its antifungal effects against pathogenic cryptococci C. neoformans.
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1.6 Scytovirin
Scytovirin (SVN) is a small lectin first isolated from aqueous extracts of the
cyanobacteria Scytonema varium. While being characterized, sequence analysis of the
9.7 kDa anti-HIV protein showed 55% similarity to the inner conserved core region of a
chitin binding protein. However, binding studies have indicated that Scytovirin does not
bind to chitin but rather large oligosaccharides (Bokesch et al. 2003). Furthermore,
Scytovirin specifically binds to Man4, the α(1–2), α(1–6), α(1–6 ) tetramannoside moiety
or D3 arm of Mannose 9-GlcNAc2 (Figure 1.3) (Adams et al. 2004). Man4 is a common
sugar moiety of high mannose glycans in viral enveloped glycoproteins and fungal Nlinked-glycans (Deshpande et al. 2008; Martínez-Duncker, Díaz-Jímenez, and MoraMontes 2014).

!-(1➝2)
D3

!-(1➝6)
!-(1➝6)

D2

D1

Figure 1.3 A diagram of the N-linked glycan Mannose 9-GlcNAc2Asn. The yellow
circles indicate mannose units. The blue squares represent N-acetylglucosamines, and
the light blue diamond indicates an asparagine amino acid. The D3 arm is Man4
labeled with its corresponding glycosidic linkages.
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Scytovirin is made up of 95 residues, which contain two 39 amino acid sequence
repeats that represent the two carbohydrate binding domains, Scytovirin domain 1 (SD1)
and Scytovirin domain 2 (SD2). The domains are separated by a proline rich linker and
exhibit a similar pattern of three aromatic amino acids (SD1, Y6, W8, F37; and SD2,
Y54, W56, F85), which form the protein’s two binding sites. Scytovirin is also
comprised of five structurally important disulfide bonds. One of the most unique
structural properties of Scytovirin is that is shows no features of extended regular
secondary structure (Figure 1.4) (R. L. McFeeters et al. 2007).
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Figure 1.4 Amino acid sequence alignment of Scytovirin’s two carbohydrate binding
domains (top) and the three-dimensional Scytovirin structure determined by solution
NMR (PDB ID: 2JMV) (bottom). The SD1 and SD2 sequences are shown in blue and
red, respectively. The aromatic triad of each domain are boxed in black, and the five
disulfide bonds are shown in yellow (Adapted from R. L. McFeeters et al. 2007). The
lack of secondary structure can be seen in the ribbon structure (bottom left) with SD1 in
blue, SD2 in red, and the linker region and termini in yellow. The carbohydrate binding
sites can be seen in the surface model structure (bottom right) in black in SD1 and cyan
in SD2. This structure was generated using Chimera 1.11.2 (Pettersen et al. 2004).
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Scytovirin’s two domains differ in carbohydrate affinity towards Man4 by
approximately six-fold with SD1 having a dissociation constant (Kd) of 40 µM and SD2 a
Kd of 250 µM. It is proposed this difference is due to the reversed middle turn in SD2
causing the side chain of F85 to be in a suboptimal position to quickly participate in
binding (H. McFeeters, Gilbert, and M. Wood 2013; R. L. McFeeters et al. 2007).
Structural engineering of Scytovirin has been shown to both improve
carbohydrate affinity and its anti-viral efficacy. Several mutations were made to residues
in regions involved in Man4 binding (Figure 1.5). Mutant Y54F improved carbohydrate
binding affinity of SD1 by four-fold (10 µM) and was found to have 3.3 times higher
affinity in SD2 (75 µM) in comparison to the wild type protein. Subsequently, this
mutant was more potent towards HIV-1 than the wild type. The aromatic residue
mutation, W56L, also increased the binding affinity of Scytovirin similarly to Y54F with
SD1 and SD2 having Kd values of 30 µM and 95 µM, respectively. In contrast, mutant
F85L significantly weakened the carbohydrate binding affinity for SD2 (425 µM) and
slightly weakened the affinity for SD1 (60 µM). Finally, the domain swapped mutants
D57N and N9D did not improve carbohydrate binding affinity. Both were found to
decrease the binding affinity by approximately two-fold with the former having Kd values
for SD1 and SD2 of 85 µM and 580 µM, respectively, and the latter having Kd values for
SD1 and SD2 of 75 µM and 575 µM, respectively (R. L. McFeeters et al. 2007; H.
McFeeters, Gilbert, and M. Wood 2013).
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W56L
D57N
N9D
F85L
Y54F

N-terminal
C-terminal

Figure 1.5 A ribbon structure of Scytovirin (PDBID: 2JMV) highlighting previously
mutated residues. Blue mutated residues resulted in stronger carbohydrate binding, while
red mutated residues caused weaker binding. Termini are labeled. (Adapted from H.
McFeeters, Gilbert, and M. Wood 2013). This structure was generated using Chimera
1.11.2 (Pettersen et al. 2004).

Like other high mannose binding lectins, Scytovirin potently inhibits HIV, Zaire
Ebola virus, and Hepatitis C (Bokesch et al. 2003; Garrison et al. 2014; Takebe et al.
2013). Recently, Scytovirin has been proven to also be effective against several strains of
the fungi C. neoformans var neoformans and C. gatti with minimum fungicidal
concentration (MFC) values as low as 500 nM. Though Scytovirin affects the capsule of
C. neoformans, the protein has been shown to localize to the fungal cell wall by
fluorescence confocal microscopy. Studies have also shown Scytovirin does not interact
with chitin leading to the hypothesis that the lectin inhibits Cryptococcus by binding to a
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mannoprotein on the cell wall surface rather than the chitin within the cell wall (Jones et
al. 2017).

1.7 Myxovirin
Only recently has there been another protein found to resemble Scytovirin. A
Basic Local Alignment Search Tool (BLAST) search of Scytovirin’s residues 3-41, SD1
of Scytovirin, showed a high amino acid sequence similarity to a portion of the first
sequence result, UniProt F8CH14, found in Myxoccocus fulvus. This sequence has 68%
identity and 79% similarity to SD1 and 82% similarity and 74% identity to SD2 (Figure
1.6).

Cloned Scytovirin-Myxovirin Sequence Alignment

*

*

**

**

Hypothetical Protein F8CH14
Signal Peptide
1

39

Myxovirin
40

Ricin B
80

107

251

Figure 1.6 Cloned protein sequence alignment of the carbohydrate binding domains
of SVN (red) and MXN (blue) with conserved aromatic patterns involved in
carbohydrate binding (boxes) and cysteines (asterisks) forming intradomain disulfide
bonds (top) (R. L. McFeeters et al. 2007). The N termini of both proteins are shown
in grey along with Scytovirin’s linker region and C terminus. Arrangement of the
hypothetical protein F8CH14 from Myxococcus fulvus with the Scytovirin-like
domain in blue (bottom) (Adapted from Jones 2017).
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In the UniProt database, the full-length hypothetical M. fulvus protein is coded by
the gene LILAB_15130 in Myxococcus fulvus (strain ATCC BAA-855 / HW-1) and is
termed “Ricin B lectin”. The description Ricin B lectin is derived from the C-terminal
region of the protein, specifically residues 107-250, which has a similar profile to a ricin
B lectin motif characteristically known for its Q-W triple repeating pattern (Hazes 1996).
The N-terminal region of the protein is a probable signal peptide followed by the
Scytovirin like domain, residues 42-79, and a linker region containing polyproline
(Figure 1.6). Because of the high sequence similarity between the carbohydrate binding
domain found in Ricin B lectin and those found in Scytovirin, the Scytovirin-like domain
was named Myxovirin (MXN) following the naming convention of high mannose
binding lectins after the genus of the organism of origin (Myxococcus) followed by -virin
(Jones 2017).
Like Scytovirin, Myxovirin was found to bind to Man9, a characteristic known to
give lectins their antimicrobial properties, but Myovirin’s specificity to Man9 has yet to
be determined. Myxovirin also has been shown to inhibit the growth of C. neoformans
strain 24067 serotype D at 23 µM, approximately twenty fold weaker than that of the two
carbohydrate binding domain containing protein Scytovirin (Jones 2017).
Though less potent, Myxovirin presents itself as more advantageous as an
antifungal therapeutic than Scytovirin. First, unlike Scytovirin, Myxovirin is composed
of a single carbohydrate binding domain which provides a better opportunity to
investigate the structure/function relationship of the Scytovirin-like domain via NMR.
Secondly, Myxovirin is also smaller than Scytovirin at 4.5 kDa making it a more
economically preferred biologic for pharmaceutical production. As part of a larger
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hypothetical lectin, Myxovirin is postulated to be more susceptible to modifications on
both termini unlike Scytovirin which loses both binding and antimicrobial activity upon
N-terminus alterations and shows a 3-7 fold decrease in activity after C-terminus
alteration (Xiong et al. 2006).

1.8 Research Project Aim
This work will focus on both improving the antifungal efficacy of the novel lectin
Myxovirin against C. neoformans and characterizing its carbohydrate binding in an effort
to further the development of high mannose binding lectins as antifungal therapeutics. In
order to characterize Myxovirin-Man9 binding, recombinant wild-type Myxovirin, mutant
forms of Myxovirin made via site-directed mutagenesis, and the N-glycan ligand (Mannose
9-GlcNAc2Asn (Man9)) were produced. Mutations of Myxovirin were made with a focus
on residues involved in carbohydrate binding to further investigate the protein-ligand
interaction. A chimera composed of the Myxovirin lectin and a known antifungal peptide
was produced to determine possible potentiation of anticryptococcal activity.
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CHAPTER TWO

METHODS

2.1 Methods
The methods described in the following sections were utilized to produce
Myxovirin and its many variants along with the Man9 binding partner to investigate
Myxovirin’s carbohydrate binding and antifungal efficacy.

2.2 Site-Directed Mutagenesis
To produce the Myxovirin mutations Y6F, Y6W, W8L, D9N, R12N, W37F, and
W37Y, a forward and reverse oligonucleotide primer were designed for each desired
mutation and commercially synthesized (Eurofins Genomics, USA). The sequences of
each mutagenetic primer pair can be found in the Appendix. A QuikChange Lightning
Site-Directed Mutagenesis Kit (Agilent Technologies, TX, USA) was used to perform all
mutagenesis reactions following the manufacturer guidelines.
A previously cloned pET-32c(+)-Myxovirin expression vector was used as the
plasmid template in site-directed mutagenesis reactions to produce each mutant. This
original expression vector contained the wild-type Myxovirin gene with the second
residue changed from a proline to a serine to preserve a thrombin cleavage site
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(LVPRGS) in which the last two residue cuts are the first two residues of the Myxovirin
protein. Additionally, the gene had two stop codons at the end of the sequence to
terminate translation. The expression vector also included BglII and XhoI restriction
sites for potential subcloning, a thioredoxin tag to aid in proper disulfide bond formation
and protein folding, and a hexahistidine tag to aid in affinity purification (Figure 2.1)
(Jones 2017).

T7 Promoter

thrombin site

thrombin site
BglII

lac operator

rbs

TrxA-Tag

6xHis

XhoI
Myxovirin

T7 Terminator

3’

Figure 2.1 Plasmid map of pET-32c(+)-Myxovirin template (top) and cloned fusion
linear DNA construct of TrxA-6xHis-MXN with proteolytic and endonuclease cleavage
sites indicated (bottom). Plasmid map was created with SnapGene Viewer 4.2.4 (GSL
Biotech LLC, USA).
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Briefly, site-directed mutagenesis was carried out with the pET-32c(+)-Myxovirin
template via polymerase chain reaction by following the thermal cycling parameters in
Table 2.1 using a MJ Mini Personal Thermal Cycler (BioRad, USA). Parameters were
determined according to the kit guidelines. After a DpnI enzymatic digest, amplicons
were transformed into E. coli DH5a competent cells. DNA was miniprepped using a
GeneJet Plasmid Miniprep Kit (ThermoScientific, MA, USA) from the transformants,
and mutations were verified by DNA sequencing.

Table 2.1 Thermal cycling parameters for site-directed mutagenesis of Myxovirin pET32c(+).
Step

Temp (°C)

Time

1

95

2 min.

2

95

20 sec.

3

60

10 sec.

4

68

3 min.

5

68

5 min.

6

4

Indefinite Storage

18 Cycles

2.3 Growth of Bacterial Cultures and Expression of Myxovirin
E. coli Origami™ B(DE3)pLysS competent cells (Novagen) were transformed
with either the wild-type or mutant pET-32(+)-Myxovirin plasmids and grown on LuriaBertani (LB) agar plates containing 20 µg/mL of carbenicillin for 16 hours at 37 °C. For
large scale cultures to be used for isothermal titration calorimetry (ITC) and antifungal

21

experiments, contents of three transformation plates were scraped into 1 L LB broth
containing 20 µg/mL of carbenicillin. For NMR spectroscopy, all colonies from two
transformed plates were scraped into 500 mL of Spectra 9 15N-labeled Media (Cambridge
Isotope Laboratories, MA, USA) also containing 20 µg/mL of carbenicillin. The cultures
were grown in a rotary shaker to an optical density at 600 nm (OD600) of ~0.6 at 37 °C at
which point they were induced with a final concentration of 1 mM isopropyl b-D-1thiogalactopyranoside (IPTG). Expression was allowed to progress for 4 hours at 37 °C
after which cells were harvested by centrifugation. Cell pellets were stored at -80 °C
until protein purification. Protein expression was confirmed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE).

2.4 Purification of Myxovirin Wild-Type and Mutant Proteins
Recombinant wild-type and all seven mutant Myxovirin proteins were purified in
two steps: metal chelation chromatography and reverse phase high-performance liquid
chromatography (HPLC). To begin, a cell pellet from a 0.5 L Spectra 9 15N-labeled or 1
L LB culture was resuspended in 20 mL of ice-cold 50 mM sodium phosphate buffer at
pH 6.8. Cells were lysed by adding 15 mg of lysozyme, 10 mM MgCl2, 20 µL of DNase
I, and 0.5 – 1 mL of protease cocktail inhibitor (Protease Inhibitor Cocktail P8465/P8849,
Sigma-Aldrich, St. Louis, MO, USA). Chemical cell lysis was allowed to occur for 30
minutes at room temperature and was then followed by mechanical lysis via sonication.
Solubility of Myxovirin was assessed by SDS-PAGE. Next, the lysate was centrifuged at
21,000 x g at 4 °C for 30 minutes to separate soluble and insoluble protein.
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In the first purification step, a 5 mL “HisTrap FF” nickel affinity column (GE
Healthcare, Uppsala, Sweden) was equilibrated with 50 mM sodium phosphate, 300 mM
NaCl, pH 7.5. Using a FPLC system, the lysate supernatant was loaded onto the affinity
column at a flow rate of 2 mL/min. and washed with the equilibration buffer until the
absorbance at 280 nm returned back to baseline. The absorbance at 280 nm was
monitored by a Pharmacia UV-1 FPLC detector (with a 280 nm wavelength filter) set to
an absorbance range of 0.05 AU. The column was then washed with 14% elution buffer
(50 mM sodium phosphate, 300 mM NaCl, 150 mM imidazole, pH 7.5) until the
absorbance at 280 nm stabilized. Subsequently, the column was washed again with 20%
elution buffer until the absorbance at 280 nm again reached a baseline. The protein was
eluted with 100% elution buffer and collected in 4 mL fractions. Samples of fractions
from each wash step and the elution step were run on an SDS-PAGE gel to evaluate the
presence of Myxovirin.
To cleave off the thioredoxin fusion protein and hexahistidine tag, 50 µL of 64
mg/mL thrombin was added to pooled eluent fractions containing Myxovirin. The
protein solution was dialyzed in a 3,500 Da molecular weight cut off (MWCO) dialysis
membrane against 1 L of 20 mM Tris-HCl, 50 mM NaCl, pH 7.6 for 16 hours at room
temperature. The cleavage reaction was quenched with 1 µL of 17 mg/mL PMSF per 1
mL of protein solution. The dialyzed protein was then concentrated to 5 mL using a
3,000 Da MWCO centrifugal concentrator.
For the second purification step, Myxovirin was purified from the hexahistidine
tag and thioredoxin fusion protein on a Waters Sunfire™ 5 µm C18 column (4.6 x 150
mm) with a HITACHI ELITE Lachrom HPLC system using a gradient pump L-2130 and
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L-2400 UV detector. The 5 mL of dialyzed protein (maximum injection volume) was
loaded onto the column and purified with a gradient of acetonitrile shown in Table 2.2.
The elution of Myxovirin was monitored with the UV detector at 280 nm and collected at
a flow rate of 0.7 mL/min. Samples of fraction from the elution peak were analyzed with
SDS-PAGE. The eluted fractions containing pure Myxovirin were pooled and the pH
was adjusted to pH 5.5 with 50 mM Tris-HCl, pH 8.0. The protein solution was then
diluted with and buffer exchanged against either 20 mM MES, pH 5.5 for ITC
experiments or 20 mM MES, 100 µM EDTA, 10 µM NaN3, pH 5.5 for NMR
experiments.

Table 2.2 Mobile phase linear gradients of HPLC purification of Myxovirin.
Buffer Gradient % Changes
Time (min.)

dH2O with 0.05%
TFA

Acetonitrile

Methanol

0-10

95-90%

5-10%.

0%

10-60

90-50%

10-50%.

0%

60-70

50-10%

50-90%

0%

70-80

10-0%

90-100%

0%

80-90

0%

0%

100%

2.5 Production of Mannose 9-GlcNAc2Asn
The production of Man9 was carried out using a procedure adapted from
(Anderson, Fernandez, and Rice 2010). The first step in producing Man9 from soy bean
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agglutinin (SBA) was the purification of SBA from soy flour. To extract the protein from
soy flour, 30 g of soy flour was dissolved in 600 mL of PBS at pH 7.4 by stirring for 16
hours at 4 °C. The soy flour/PBS mixture was centrifuged at 9000 x g for 15 minutes and
the supernatant was gravity filtered through Fisherbrand® P8 Grade filter paper (Fisher
Scientific, PA, USA). SBA was purified using a customized Sepharose Ncaproylgalactosamine affinity column (50 mL column volume) prepared by a coupling
reaction similar to that described in (Anderson, Fernandez, and Rice 2010). The affinity
column was washed with 50 mL of dI-H2O (1 column volume) and equilibrated with 3
column volumes of PBS after which the supernatant filtrate was applied to the column by
gravity flow. The column was subsequently washed with PBS until the absorbance at
280 nm returned to a stable baseline. The elution of protein was monitored by detecting
the absorbance at 280 nm using a Pharmacia UV-1 FPLC detector (with a 280 nm
wavelength filter) set to an absorbance range of 0.05 AU. SBA was eluted with 0.2 M Dgalactose in PBS and collected in 8 mL fractions. Fractions containing SBA were pooled
and dialyzed in 12,000 Da MWCO tubing against 1 L dI-H2O at room temperature
overnight followed by another dialysis against fresh dI-H2O for an additional 3 hours.
SBA was then lyophilized.
Lyophilized SBA was proteolytically digested with Pronase (Roche, Mannheim,
Germany) to separate Man9 from the protein. To accomplish this, SBA was reconstituted
in 8 mL of 100 mM HCl and denatured at 50 °C for 15 minutes. The pH was adjusted by
adding 600 µL of 1 M NaOH which results in a formation of a gel. The gel was
dissolved by adding of 2 mL of dH2O and 100 µL of 2 M NaOH. The pH was then
adjusted to a pH between 7-8 (the optimal pH range for Pronase activity) using 1 M HCl.
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In order to aid in complete digestion of SBA, SDS was added at a final concentration of
0.5%. An amount of 7 mg Pronase in 2 mL of 30 mM CaCl2, 50 mM Tris, pH 8.5 was
added to the SBA digestion mixture. The digestion was allowed to occur for 24 hours at
37 °C at which point another 5 mg Pronase in 1 mL 30 mM CaCl2, 50 mM Tris, pH 8.5
was added to the mixture; the digestion was then allowed to proceed for another 24 hours.
Complete protein digestion was verified with SDS-PAGE. If complete digestion was not
achieved, additional Pronase was added and digestion was prolonged.
To isolate Man9 from the digestion mixture, Man9 was purified via size exclusion
chromatography. In brief, the digested SBA mixture was centrifuged at 3,700 x g for 10
min., and the supernatant was lyophilized. A Sephacryl S-100 HR size exclusion column
(2.5 x 90 cm) (GE Healthcare, Uppsala, Sweden) was equilibrated with 1 column volume
of filtered 10 mM acetic acid at a flow rate of 1 mL/min. Next, the freeze-dried
supernatant was reconstituted in 4 mL dI-H2O and loaded onto the column via FPLC.
Man9 was eluted with the equilibration buffer at a flow rate of 1 mL/min and collected at
8 mL fractions until the peak indicative of free amino acids in the digestion mixture was
observed (detected by UV at an absorbance of 280 nm) and returned back to baseline.
From the eluted fractions, Man9 was detected and quantified by the phenol sulfuric assay
(PSA) measuring visible absorbance at 490 nm (Dubois et al. 1956). Finally, Man9
containing fractions were lyophilized and stored in a desiccator until use in carbohydrate
binding experiments.
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2.6 Isothermal Titration Calorimetry (ITC)
ITC experiments were performed with wild-type and all mutant Myxovirin at 25
°C in a NanoITC Low Volume isothermal titration calorimeter (TA Instruments, DE,
USA) with an active cell volume of 190 µL. Man9-GlcNAc2Asn was resuspended in the
buffer Myxovirin proteins were dialyzed in (20 mM MES, pH 5.5) to expunge/minimize
the baseline noise. Protein concentration was determined by measuring UV absorbance
at 280 nm, and the ligand concentration was determined by PSA. During different
titrations, 1.49 µL of Man9 (between 0.33 – 1 mM) were injected into a cell containing
50 – 75 µM Myxovirin under constant stirring (200 rpm). Fitting of the resulted
isotherms after excluding the first two data points was performed with NanoAnalyze™
software version 3.10.0 (TA Instruments). The ITC data were blanked by subtracting the
control thermogram (MES buffer titrated with Man9), and the resulting points were fitted
to an independent binding model assuming a 1:1 binding stoichiometry between
Myxovirin and Man9.

2.7 Chemical Shift Perturbation Mapping
Concentrated 15N labeled samples of wild-type and all seven Myxovirin mutants
were used for NMR titration experiments with Man9-GlcNAc2Asn. Protein and ligand
concentrations were determined by a bicinchoninic acid (BCA) assay and PSA,
respectively. All data was recorded at 298 K on a 500 MHz Varian Inova spectrometer
with a room temperature probe. Briefly, 200 µL samples of Myxovirin in 20 mM MES,
100 µM EDTA, 10 µM NaN3, pH 5.5, 5% D2O in 5 mm Shigemi NMR tubes were
titrated with Man9 in increasing ratios of Man9:Myxovirin. The starting protein
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concentration was 200 µM. In general, 15N-HSQC spectra were acquired for the
following Man9:Myxovirin concentration ratios: 0:1, 0.3:1, 0.6:1, 1.2:1, 2.4:1, and 4.8:1
with additional spectrum for Y6F and D9N at 19.2:1. All data were processed with
nmrPipe (Delaglio et al. 1995) using a Gaussian window function, zero filling to twice
the data size, and discrete Fourier Transform. Spectra were analyzed using NMRFAMSPARKY (Lee, Tonelli, and Markley 2015). Peaks were picked manually with center
positions determined from Lorentzian fits to the entire peak. The carbohydrate binding
affinity for wild-type and Myxovirin mutants was determined from best fits of percent of
bound protein versus the molar ratio of carbohydrate to protein using a custom MATLAB
(Mathworks, MA, USA) script provided by Dr. David Fushman (University of Maryland,
College Park MD).

2.8 Synthesis and Production of Lectin/Antifungal Peptide Chimera
An E. coli optimized sequence for a Myxovirin/human lactoferrin residues 1-11
(hLF(1-11)) chimera was designed and commercially synthesized by GenScript (NJ,
USA). The sequence included the wild-type Myxovirin gene directly followed by a
sequence for a (Gly4Ser)5 linker and the hLF(1-11) gene. The fourth Gly4Ser repeat in
the linker was also designed to include a point mutation causing the third Gly to change
to an Arg. More importantly, this missense mutation allowed for a NotI restriction site to
be inserted to retain the opportunity to lengthen the linker or switch out the hLF(1-11)
gene with another known antifungal peptide. Additionally, BglII and XhoI restriction
endonuclease sites were included at the 3’ end and 5’ end, respectively. The full
sequence was cut out of the pUC57 synthesis vector and ligated into the original pET-
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32c(+)-Myxovirin expression vector. A restriction digest of the pUC57 vector and the
pET-32c(+)-Myxovirin expression vector was performed by mixing either 6 µL of the
pUC57 plasmid (161.95 ng/µL) or 10.5 µL of the pET-32c(+)-Myxovirin plasmid (18.29
ng/µL), 1.5 µL 10x Green FastDigest buffer (ThermoScientific, MA, USA), 1 µL BglII,
and 1 µL XhoI. Nuclease free dI-H2O was added to each mixture for a total reaction
volume of 15 µL. Each reaction mixture was vortexed, allowed to incubate at 37 °C for
15-30 minutes and run on a 1% agarose gel at 120 mA to separate the DNA fragments.
The cut Myxovirin-hLF(1-11) gene and the double cut pET-32c(+) vector were extracted
and purified from the gel with a GeneJET Gel Extraction Kit (Fermentas Life Sciences,
MA, USA). The cut gene was then ligated into the double cut vector by combining 4 µL
5x rapid ligation buffer, 9 µL (BglII/XhoI cut) gene insert, 3 µL (BglII/XhoI cut) pET32c(+) vector, 1 µL T4 ligase, and nuclease free dH2O up to 20 µL. The ligation reaction
was allowed to proceed for 5 minutes at room temperature at which point the reaction
was transformed into E. coli DH5a cells. A DNA miniprep was performed (GeneJet
Plasmid Miniprep Kit, ThermoScientific, MA, USA) using the resulting transformants,
and proper ligation was confirmed by DNA sequencing. Myxovirin-hLF(1-11) was
expressed and purified as described in Chapter 2.3 and 2.4. After dialysis against 20 mM
MES, pH 5.5, the protein was lyophilized and resuspended in sterile PBS pH 7.4 for
antifungal susceptibility testing.
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2.9 Microdilution Antifungal Screening
To determine the activity of the Myxovirin-hLF(1-11) chimera against
Cryptococcus neoformans, a Clinical and Laboratory Standards Institute (CLSI) broth
microdilution assay was performed. C. neoformans serotype D strain 24607 was grown
on potato dextrose agar (PDA) for 72 hours at 37 °C before 3 mL of potato dextrose broth
(PDB) was inoculated with a single colony from the PDA plate. The liquid culture was
then grown at 37 °C for 72 hours in a rotary shaker at 150 rpm. Cells were counted with
a Bright-Line™ hemocytometer and were diluted to a concentration of 4 x 103 cells/mL
using MOPS (3-(N-morpholino) propanesulfonic acid) buffered RPMI (Roswell Park
Memorial Institute) medium.
Antifungal activity against C. neoformans was determined by a broth
microdilution assay in a 96-well round bottom plate. Briefly, 100 µL of MOPS buffered
RPMI pH 7.0 was added to each well in the 96-well plate. Next, 100 µL of a sample or
control was added to the first well in each row and serially diluted 2-fold down the
column. Lastly, 100 μL of the prepared 4 x 103 cells/mL inoculum in MOPS buffered
RPMI was added to each well in the plate resulting in a final cell concentration of 2 x 103
cells/mL in each well. Plates were incubated at 37 °C without agitation for 72 h. The
protein samples tested included 160 µM of wild-type Myxovirin and Myxovirin-hLF(111) and 730 µM (1 mg/mL) of hLF(1-11) having final concentrations in the well in first
row at 40 µM and 183 µM, respectively. Protein concentration was determined by
measuring UV absorbance at 280 nm. The AFP, hLF(1-11), was commercially obtained
as a lyophilized powder and resuspended in sterile PBS pH 7.4 like the other protein
samples. Amphotericin B (AmpB) in %100 DMSO was used as a positive control, while
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100% DMSO and PBS were used as carrier controls to control for the effects of the
solvent and buffer. RPMI alone (cells only) was used as the negative control. The
minimum inhibitory concentration (MIC) for each sample was visually determined as the
last well with no cell growth/turbidity.
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CHAPTER THREE

RESULTS & DISCUSSION
3.1 Cloned Mutants
Mutations of Myxovirin were engineered in an effort to increase the lectin’s
carbohydrate affinity and subsequently improve its antifungal efficacy. Based on
mutations previously introduced to Scytovirin, Myxovirin residues Y6, W8, D9, R12, and
W37 were selected for investigation in this study. Myxovirin mutants Y6F, W8L, D9N,
R12N, and W37F were introduced to mimic Scytovirin’s higher affinity domain SD1.
All aromatic mutations, including Y6W and W37Y, were included because of the direct
role the aromatic residues play in carbohydrate binding. Mutations D9N and R12N were
chosen because the role of Asp9 in carbohydrate binding is still poorly understood and
because of the close proximity of Arg12 to the first two residues in the aromatic triad.
These mutations will help in both better understanding the structure/function relationship
of high mannose binding lectins and furthering their potential as antifungal therapeutics.
All mutations were introduced to Myxovirin by site-directed mutagenesis and were
successfully confirmed through DNA sequencing.
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3.2 Expression and Purification of Recombinant Wild Type and Mutant Myxovirin
Myxovirin and its mutants were expressed and purified as previously described.
Along with the wild-type protein, all seven mutants were grown in both rich and 15N
isotope labeled minimal media for ITC and NMR experimentation, respectively. All
mutants responded to the same growth and expression conditions as wild-type Myxovirin,
with no noticeable change overexpression. Overexpression of the fusion proteins was
verified as dark 19.6 kDa molecular weight bands on an SDS-PAGE gel (Figures 3.1).
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Figure 3.1 SDS-PAGE showing expression of wild-type MXN (top) and all verified
MXN mutants (bottom). Represented are the molecular weight ladder (MW) and
samples of uninduced (-) cultures and cultures induced with IPTG (+). The dark bands
indicated by the arrow designate the position and size of the MXN fusion proteins.
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Following chemical and mechanical cell lysis, Myxovirin was found to be almost
entirely soluble seen in the supernatant fraction (S) shown in Figure 3.2 with dark bands
being observed in the total cell lysate and the lysate supernatant gel lanes and a faint band
in the insoluble lysate pellet gel lane. Solubility of Myxovirin remained the same
between both expression conditions (rich and minimal media) and across all mutants.
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15

Figure 3.2 SDS-PAGE of wild-type MXN solubility from expression in minimal media
(MW for molecular weight ladder, T for total cell lysate, S for soluble lysate supernatant,
and P for insoluble lysate pellet samples). MXN fusion protein is indicated by the red
arrow.

Metal chelation chromatography, with a nickel affinity column, was used to
purify the Myxovirin fusion proteins. Both the wild-type and mutant fusion proteins
followed the same elution profile as seen in Figure 3.3. By visual analysis of SDSPAGE, the fusion protein was greater than 80% pure as shown in Figure 3.4.

34

100
90
80

UV 280 Absorbance

70
60
50
40
30
20
10
0
Load

Wash

Elution

Figure 3.3 Elution profile for FPLC metal chelation purification of wild-type MXN
fusion protein washed with 21 mM and 30 mM imidazole and eluted with 150 mM
imidazole. The peak comprised of fractions containing MXN is highlighted in light blue.
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Figure 3.4 SDS-PAGE of FPLC Ni2+ affinity purification of wild-type MXN fusion
protein (MW for molecular weight ladder and FT for flow-through of the loaded
supernatant). Purified MXN fusion protein is indicated by the red arrow.

Along with the wild-type protein, all mutants were successfully separated by a
thrombin cleavage between the thioredoxin/hexahistidine tag and the Myxovirin protein.
Proteolysis was quenched with a serine protease inhibitor, PMSF, and confirmation of the
cleavage was visualized with SDS-PAGE as seen through the comparison of the uncut
and cut lanes in Figure 3.6. Reverse phase HPLC was used to separate the Myxovirin
protein (peak A) from the other cleaved fragments (i.e. thioredoxin/hexahistidine tags and
a small protein fragment between the two thrombin sites) and any remaining background
protein from the FPLC purification (peak B). Both peaks saturated the HPLC detector
due to the highly concentrated sample loaded onto the column, however, both
predominantly appeared as single peaks with trailing shoulders indicative of unfolded
protein. The Myxovirin mutants showed the same general elution profile as the wild-type
despite some discrepancies where thioredoxin elutes which is likely attributed to
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variations in remaining background protein. Also, in comparison to the wild-type,
Myxovirin mutants showed slight shifts in retention times due to the change in
hydrophobicity and electrostatic interactions induced by the mutation (Figure 3.5). The
purity of eluted Myxovirin was assessed by SDS-PAGE (Figure 3.6). As to collect
properly folded protein for use in carbohydrate binding experiments, only fractions
preceding the peak shoulder where pooled and dialyzed.
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Figure 3.5 HPLC chromatogram of mutant Y6F (red) overlaid with wild-type MXN
(blue). Peak A is MXN and Peak B is thioredoxin/hexahistidine fusion protein along
with any remaining background protein from metal chelation chromatography.
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Figure 3.6 SDS-PAGE of reverse phase HPLC purification of wild-type MXN. Prethrombin cleavage MXN-thioredoxin is denoted by “Uncut”, post-thrombin is denoted by
“Cut”, and eluted MXN fractions are boxed in red.

3.3 Isolation of Mannose 9-GlcNAc2Asn
To determine the carbohydrate binding affinity of Myxovirin and its mutants, its
ligand, Mannose 9-GlcNAc2Asn, was acquired. The N-linked glycan was isolated from
soy bean agglutinin (SBA) found in soy flour. SBA is a 120 kDa tetrameric protein
which possesses a Man9 moiety on each of its four subunits. To isolate Man9, SBA was
first extracted and purified from soy flour then proteolytically digested to release Man9.
The high mannose sugar was then separated from the other components in the digestion
mixture (i.e. amino acids or small peptide fragments) by size exclusion chromatography.
To initially purify SBA from soy flour, a custom Sepharose Ncaproylgalactosamine affinity column was prepared (Figure 3.7) (Anderson, Fernandez,
and Rice 2010). From five independent purifications, an average of 104 mg of dry
weight SBA was recovered after lyophilization from 30 g of soy flour resulting in a yield
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of 0.35%. Thus, the affinity column bound approximately 2.1 mg SBA per mL of resin.
Purified SBA is shown in Figure 3.8. In an attempt to increase the yield of a single SBA
purification, 40 g and 70 g of soy flour were dissolved and purified; however, increasing
the amount of soy flour did not significantly increase the yield of SBA indicating the
binding capacity of the column was at its maximum. In another attempt to efficiently
produce more SBA for Man9 isolation, an additional Sepharose N-caproylgalactosamine
affinity column (~30 mL column volume) was prepared in order to run in parallel with
the original 50 mL column. Using this column, from five independent purifications, an
average of 131 mg of dry weight SBA was recovered from 30 g of soy flour resulting in a
percent yield of 0.44%. Therefore, the newer, freshly prepared affinity column bound
approximately 4.4 mg SBA per mL of resin. With the addition of another custom SBA
affinity column, greater than 200 mg of SBA could be collected with two purifications
occurring simultaneously.
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Figure 3.7 Elution profile of SBA purification eluted with 0.2 M D-galactose on a
custom Sepharose N-caproylgalactosamine affinity column. The peak comprised of
fractions containing SBA is highlighted in light blue.
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Figure 3.8 SDS-PAGE of purification of SBA (MW for molecular weight ladder, “Mix”
for soy flour/PBS mixture, “Sup” for supernatant of the mixture, and FT for flow-through
of the loaded supernatant). Purified SBA is indicated by the arrow.

Man9 was released from SBA through an enzymatic digestion. First, SBA was
denatured by the addition of acid and heating to 50 °C for 15 minutes. Pronase, a mixture
of nonspecific proteases, was added at a final concentration of 0.5-2 mg per milliliter of
solution to digest SBA into individual amino acids, releasing Mannose 9-GlcNAc2Asn.
This enzyme mixture was used instead of the PNGase F, commonly used to release Nlinked glycans, since PNGase F will not remove glycans containing an alpha-(1,3)-linked
fucose core generally found on plant glycoproteins. For Pronase to be optimally active,
the pH was increased to between 7 and 8. This was done with the addition of sodium
hydroxide which ultimately caused the denatured protein to become insoluble resulting in
the formation of a gel. Both H2O and NaOH were added to dissolve the gel; however,
this caused the pH to increase to 11 which is outside the working pH range of Pronase.
To decrease the pH to between 7 and 8, 1 M HCl was titrated into the protein solution
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resulting in soluble denatured protein. From this point, Pronase was added and the
digestion reaction was allowed to proceed.
Upon verifying SBA digestion with SDS-PAGE, complete digestion was not
observed after 48 hours. This can be seen in Figure 3.9 in lane (B) which exhibits a high
molecular weight band at around 120 kDa which is most likely SBA in its tetrameric
state. Even after the addition of more Pronase and implementing a longer incubation
time, undigested protein still remained (Figure 3.9 lanes (C) and (D)). SBA is a highly
stable lectin and forms aggregates upon its lyophilized state thus potentially making it
more resistant to digestion (Sinha and Surolia 2005; Lotan, Lis, and Sharon 1975). In an
attempt to further denature SBA and improve digestion, a final concentration of 0.5%
sodium dodecyl sulfate (SDS) was added to the protein solution. This concentration was
chosen because Pronase is still active in the presence of 0.5% SDS. With the addition of
SDS, complete digestion was seen at 48 h (Figure 3.10). Consequently, the addition of
SDS was included in all subsequent SBA digestions.
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Figure 3.9 SDS-PAGE of a 237 mg SBA Pronase digestion. Lane (A) represents predigested SBA as indicated by the arrow appearing in its monomeric form at ~30 kDa and
its tetrameric form at 120 kDa. Lanes (B), (C), and (D) represent 48 h, 72 h, and 96 h
samples post the initial addition of Pronase, respectively. A faint band of undigested
protein can be seen in lane (D).
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Figure 3.10 SDS-PAGE of a 258 mg SBA Pronase digestion with 0.05% SDS. Lane (A)
represents pre-digested SBA as indicated by the arrow appearing in its monomeric form
at ~30 kDa. Lanes (B) and (C) represent 24 h and 48 h samples post the initial addition
of Pronase, respectively. Faint bands of undigested protein can be seen in lane (B). Lane
(D) represents the supernatant of the digestion mixture.
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Man9 was first purified from the amino acid/sugar digestion mixture on a
Superdex 75 sizing column. Every other eluent fraction from 38 to 80 was analyzed by
the phenol sulfuric acid assay (PSA) to detect the presence of carbohydrate. Out of the
many assays used to detect and determine the total concentration of carbohydrates in a
sample, the PSA was chosen as it is considered to be the most sensitive and reliable
method. This colorimetric assay is also more advantageous than others because it is more
suitable for the analysis of polysaccharides, inexpensive, and its reagents can be readily
available. From the PSA, it was determined fractions 60-63 contained the majority of
Man9. These fractions, however, overlapped considerably with the elution of short
peptide fragments or aromatic amino acids (fractions 60 and on) from the digestion
(Figure 3.11).
To improve the separation of Man9 and the other digestion components, another
size exclusion column was prepared using Sephacryl S-100 High Resolution (HR) resin.
In comparison to Superdex 75 which has a fractionation range of 3,000–70,000 Da,
Sephacryl S-100 HR has a fraction range of 1 × 103 – 1 × 10⁵ Da and is more suitable for
the purification of polysaccharides. As shown in Figure 3.12, it was determined the
Sephacryl S-100 HR column slightly improved the separation of N-linked Man9
(1,997.79 Da) as the sugar was found in fractions 45-56 which eluted mostly before the
large increase in absorbance at 280 nm indicative of small peptide fragments or aromatic
amino acids. Accordingly, the Sephacryl S-100 HR size exclusion column was used to
purify Man9 in all further preparations.
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Figure 3.11 Size exclusion chromatogram of Man9 purification from a 237 mg SBA
digestion on a Superdex 75 sizing column. The black solid trace shows the elution of
short peptide fragments and free amino acids by monitoring the absorbance at 280 nm.
The blue dashed trace displays the elution of Man9 determined by detection of
carbohydrates at an absorbance at 490 nm via the PSA after purification.
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Figure 3.12 Size exclusion chromatogram of Man9 purification from a 258 mg SBA
digestion on a Sephacryl S-100 HR sizing column. The black solid trace shows the
elution of short peptide fragments and free amino acids by monitoring the absorbance at
280 nm. The blue dashed trace displays the elution of Man9 determined by the detection
of carbohydrates at an absorbance at 490 nm via the PSA after purification.
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The PSA was also used to quantify Man9 after each purification. It was
determined 2.4 mg of Man9 was produced from a digestion of 258 mg of SBA. The
entire process was repeated until a sufficient amount of Man9 was collected for
carbohydrate binding experiments with wild-type Myxovirin and all seven mutants.

3.4 ITC Carbohydrate Affinity Determination
To first study the interaction between Myxovirin and Man9, isothermal titration
calorimetry (ITC) was used to determine both the carbohydrate binding affinity and the
thermodynamic binding parameters of this interaction. Wild-type Myxovirin was first
tested with Man9 by titrating 1 mM aliquots of the glycan into 75 µM of buffer
containing protein. When fitting the integrated heat data to an independent (one site)
binding model, the first two points were eliminated to account for manual shaking and
micro-bumping while inserting the syringe with the ligand into the cell with the protein.
After fitting the data, it appeared that the interaction of Myxovirin binding to Man9 was
both enthalpically and entropically favorable process as the ∆H and -T∆S were -8.741
kJ/mol and -21.757 kJ/mol, respectively (Figure 3.13). Also, from this initial experiment,
Myxovirin bound more tightly to Man9 than both of Scytovirin’s carbohydrate binding
domains individually, binding with a dissociation constant of Kd = 4.5 x 10-6 M.
However, the apparent binding stoichiometry (n value) was 0.60 instead of the expected
1.0 predominantly attributed to potential inaccuracy in determining the concentration of
Man9 with the possibilities of either contaminates in the ligand or the protein being only
partially active as well.
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Figure 3.13 Corrected raw heat data and binding isotherms for 1 mM Man9 titrated into
75 µM wild-type MXN.

Using the same conditions (1 mM of Man9 and 75 µM of Myxovirin), mutants
Y6F, W8L, and W37F were also tested. All three mutants, however, did not show
binding as the fitted integrated heat data resulted in flat isotherms. To confirm the
structural integrity of these mutants, NMR studies were conducted as discussed later
(Section 3.5).
When testing the remaining mutants (Y6W, W37Y, D9N, and R12N), the
concentrations of the ligand and protein were changed to 0.33 mM and 50 mM,
respectively. The concentration of Man9 was decreased to reduce the background noise
from the ligand and prevent the masking of the signal. The Myxovirin concentration was
also decreased to keep the C value (C = n*[Titrand]/Kd) within the optimal range to
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maximize confidence in the fit parameters. The thermodynamic parameters suggest all
mutants bind to Man9 in a highly enthalpically driven process opposing an entropic
penalty (Table 1.3 and Figures 3.14 – 3.15). Out of these four mutants, W37Y seemed to
bind the tightest to Man9 with a binding dissociation constant Kd = 6.9x10-7 (M). Again,
the n value for each mutant did not agree with an independent model of one Man9 to one
Myxovirin. However, for relative comparison, the same stock of Man9 was used for all
titrations. The consistent value of n indicated the same stoichiometry of Man9 binding,
with inaccuracy of the carbohydrate concentration assumed to account for a majority of
the discrepancy from the 1:1, n=1.0 value assumed. Given the question of structural
integrity for the inactive mutants, characterization of these mutants was also conducted.
It was found that the affinities in Table 3.1 cannot be reliably compared since they do not
all represent purely binding events as discussed later (Section 3.5).

Table 3.1 ITC results for Man9 titrated into mutant MXN.
MXN
Sample

[Man9]
(mM)

[MXN]
(µM)

n

Kd
(M)

ΔH
(kJ*mol-1)

ΔS
(J*mol-1 *K-1)

-TΔS
(kJ*mol-1)

Y6W

0.33

50

0.17

9.7x10-7

-111.8

-259.8

77.4

W37Y

0.33

50

0.17

6.9x10-7

-89.93

-183.7

54.7

0.17

-7

-112.5

-267.1

79.6

-113.4

-265.5

79.1

D9N
R12N

0.33
0.33

50
50

0.17

1.8x10

-7

10.05x10
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Figure 3.14 Corrected raw heat data and binding isotherm for 0.33 mM Man9 titrated
into 50 µM aromatic Myxovirin mutants Y6W (top) and W37Y (bottom).
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Figure 3.15 Corrected raw heat data and binding isotherm for 0.33 mM Man9 titrated
into 50 µM natural residue difference Myxovirin mutants D9N (top) and R12N (bottom).
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Two trials of 0.33 mM Man9 titrated into 50 µM wild-type Myxovirin were
performed as controls to compare the mutants against. In comparison to the preliminary
experiment with 50 µM wild-type Myxovirin, the dissociation constant was about twofold different, decreasing from 4.5 µM to approximately 2 µM (Table 3.2 and Figure
3.16). The carbohydrate affinity of the mutants did not significantly improve in
comparison to the wild-type protein. In these two wild-type titrations, the interaction
between wild-type Myxovirin and Man9 was enthalpically favorable but had a larger
entropic penalty than the mutants. Similar to the mutants, the n value of the wild-type
was 0.16 ± 0.01.

Table 3.2 Control ITC results for Man9 titrated into wild-type (WT) MXN.
MXN
Sample

[Man9]
(mM)

[MXN]
(µM)

n

Kd
(M)

WT Trial 1

0.33

50

0.17

50

WT Trial 2

0.33

ΔH
(kJ*mol-1)

ΔS
(J*mol-1 *K-1)

-TΔS
(kJ*mol-1)

1.7x10-6

-132.0

-332.2

99.0

0.16

-6

2.1x10

-117.3

-284.7

84.8

avg

0.16

1.9x10-6

-124.7

-308.5

91.9

stdev

0.01

2.8x10-7

10.4

33.6

10.0
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Figure 3.16 Corrected raw heat data and binding isotherms for two control trials for 0.33
mM Man9 titrated into 50 µM wild-type MXN Trials 1 (top) and 2 (bottom).
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3.5 NMR Carbohydrate Affinity Determination
To verify the structural integrity all of the Myxovirin mutants and complement the
determination of carbohydrate affinities by ITC, NMR chemical shift perturbation (CSP)
was performed. Peaks for the wild-type Myxovirin 15N-HSQC spectrum were assigned
based on previously collected triple resonance backbone sequential assignment spectra
(Jones 2017) (Figure 3.17). To characterize the carbohydrate binding of the wild-type
protein and mutants, Man9 was titrated in increasing concentrations from 0:1, 0.3:1,
0.6:1, 1.2:1, 2.4:1, and 4.8:1 Man9:Myxovirin.
Several residue peaks displayed large chemical shift differences in the spectra
collected for wild-type Myxovirin upon the addition of Man9 indicating carbohydrate
binding (Figure 3.18). Out of the three exchange rate regimes commonly observed in
CSP mapping (i.e. fast, intermediate and slow exchange), these residues displayed slow
exchange. Fast exchange or weak binding is observed when the interconversion between
the free protein and ligand-bound states occurs so fast during the detection period of the
NMR titration experiment that only one single resonance is observed as weighted average
of the chemical shifts for each state. In contrast, slow exchange or tight binding results in
two distinct resonances for each titration as the ligand remains bound to the protein
throughout the entire detection period. Therefore, as more ligand is titrated in, the
intensity of the free protein peak gradually decreases until it is no longer observed while
the bound protein peak grows in intensity as the binding site is saturated.
In previous studies, residues in Scytovirin domain 1 (SD1) exhibited intermediate
exchange, while residues in Scytovirin domain 2 (SD2) exhibited fast exchange (R. L.
McFeeters et al. 2007). As Myxovirin demonstrated slow exchange, the interaction
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between the lectin and the glycan was expected to be stronger than that of Scytovirin
based on the observed exchange regime. Examples of slow exchange in wild-type
Myxovirin can be seen by distinct peak shifts for residues D9, W8, N13, and R12, in
Figure 3.18.

55

Figure 3.17 500 MHz 1H-15N-HSQC of 15N labeled wild-type Myxovirin at 298 K. Peak
assignments (black) are denoted with residue 1 corresponding to residue 40 in the
F8CH14 sequence.
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Figure 3.18 Chemical shift perturbation mapping of wild-type Myxovirin binding to
Man9. The 15N-HSQC spectrum for each titration are shown overlaid in one spectra (top)
with zoomed regions for three residue peaks showing slow exchange at each titration
point (bottom). Man9 was titrated into Myxovirin in increasing concentrations from red
(0:1 Man9:MXN) to coral (0.3:1) to yellow (0.6:1) to green (1.2:1) to blue (2.4:1) to
magenta (4.8:1).
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To determine the carbohydrate affinity of wild-type Myxovirin, peak volumes
were calculated for the ligand-bound peaks of seven residues exhibiting slow exchange.
The percent change in peak volume was calculated in terms of the appearing bound peak
with 100% bound being determined at complete protein saturation. Thus, the percent
change in peak volume was expressed as the percent change of protein bound to the
ligand. Dissociation constants were determined for each residue by plotting the
percentage of protein bound to known concentrations of Man9 and Myxovirin used in
each titration and then fitting the data to a single binding site model using least squares
regression analysis. (The addition of a second binding site did not lead to a statistically
significant increase in the fitting of the binding data; thus, the single site model is
justified.) An example of one of the fittings is shown in Figure 3.19. By averaging the Kd
values of the seven residues exhibiting slow exchange rates, the wild-type dissociation
constant was estimated to be 51 µM.
The difference in the dissociation constant determined by ITC (1.90 ± 0.28 µM)
and the Kd determined by NMR can again be possibly attributed to the potential
inaccuracy of the carbohydrate concentration which was presumed to be the source of the
discrepancies in the calculated n value from ITC. Compared to the binding affinities for
Man4 of both of Scytovirin’s domains (40 µM for SD1 and 250 for SD2 µM), Myxovirin
binds tighter to Man9 than SD2 and has approximately the same affinity towards the
glycan as SD1. Myxovirin’s tight binding along with being less potent against C.
neoformans than Scytovirin leads to question the effect of oligosaccharide specificity on
fungal inhibition.
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Figure 3.19
Example of single site binding fit of residue W8 in wild-type Myxovirin.
The red asterisks are the measured data points. The green circles represent the data
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The mutations Y6F, Y6W, and D9N were found to change Myxovirin’s structural
integrity resulting in partially unfolded protein (Figure 3.20 top). Due to poor chemical
shift dispersal and the absence of the initial peaks used in the calculation of the Kd for the
wild-type protein at 0:1 Man9:Myxovirin, these mutants were left out of affinity analysis.
Despite being partially unfolded, these mutants still seemed to interact with Man9 as
peaks which were not present before the addition Man9 began to appear as Man9 was
titrated in at increasing concentrations. An example of this is shown for the Y6F mutant
by comparing the two NMR spectral overlays in Figure 3.20. Backbone amide peaks in
the 0:1 Man9 spectrum for these mutants (Y6F, Y6W, and D9N) may not have been
initially present due to the protein being in various unstable conformational forms or
different population states resulting in their signals being masked by noise. However, as
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Man9 was titrated in, it is postulated the varied conformations of these mutants began to
return to a more stable fold by binding to Man9 as seen by the appearance of peaks at
higher concentrations of Man9 in the same chemical shift region as the bound peaks
shown by wild-type Myxovirin (Figure 3.21). It also should be noted the residues which
were not initially present at 0:1 Man9:Myxovirin were those near the N-terminal region
of the protein; however, other residues near the C-terminus such as W37 and W37ε were
present in the initial spectra indicating the mutated residues (Y6 and D9) aid in the
stability of interactions between neighboring residues such as W8, D9, and R12 (Figure
3.21).
These observations made in NMR are consistent with the thermodynamic
parameters determined by ITC for each of these mutants. As Man9 was added to the
mutants, both the dynamic moving protein and freely rotating mannose ligand, went from
a disordered state to a more ordered state upon binding. The increase in protein stability
and fixation of the ligand corresponds with the negative change in entropy (∆S) observed
in ITC. Additionally, the negative change in enthalpy observed for these mutants
indicates formations of energetically favorable noncovalent interactions such as hydrogen
bonds upon Man9 binding. The resulted structural changes of these three mutations not
only confirm these residues are involved in Myxovirin carbohydrate binding but also
suggest that they greatly contribute to the stability of the lectin.
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Figure 3.20 15N-HSQC of mutant Y6F (red/magenta) overlay on wild-type Myxovirin
(black). The top spectrum is an overlay of the mutant and wild-type protein at 0:1 Man9:
MXN, and the bottom spectrum is an overlay of the mutant and wild-type protein at
4.8:1. The very different backbone fold is indicated by the very different peak positions
compared to wild-type (top). The mutant backbone fold mimics wild-type peak positions
once Man9 is added (bottom).
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ε

Figure 3.21 Multiple residues shown to shift in wild-type Myxovirin are absent in mutant
Y6F at 0:1 Man9:MXN. As Man9 was titrated into Y6F in increasing concentrations
from red (0:1 Man9:MXN) to coral (0.3:1) to green (1.2:1) to magenta (4.8:1) mutant
bound peaks began to appear in close proximity to bound peaks of wild-type Myxovirin.
At 0:1 Man9:MXN, the black x represents the position of the free wild-type peak. At
4.8:1 Man9:MXN, the black x represents the position of the bound wild-type peak at
complete saturation.
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Using the same method and residues used to analyze slow exchange binding for
wild-type Myxovirin, mutant R12N was estimated to have a dissociation constant of 77
µM showing no improvement to Myxovirin carbohydrate binding. Agreeing with the
ITC results, mutant W8L did not bind Man9 as shown by no observable changes in
chemical shifts for any peaks in Figure 3.22. While the mutation W56L in Scytovirin
increased the affinity in both domains, this mutation (W to L) in Myxovirin’s one
carbohydrate binding domain eliminated carbohydrate binding altogether. It thus appears
the second aromatic residue is essential for Man9 binding for a single carbohydrate
binding domain.

Figure 3.22 Chemical shift perturbation mapping of mutant W8L binding to Man9.
Man9 was titrated into mutant W8L in increasing concentrations from red (0:1
Man9:MXN) to coral (0.3:1) to yellow (0.6:1) to green (1.2:1) to blue (2.4:1). The 15NHSQC spectrum for each titration are shown overlaid exhibiting no apparent changes in
chemical shifts signifying no carbohydrate binding.
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Upon acquiring the first 15N-HSQC spectra for mutant W37F (0:1
Man9:Myxovirin), it was observed that there were missing cross peaks in the 2D
spectrum and the peaks that were present were not well resolved. Despite the poor initial
spectrum, two titration points were performed for mutant W37F at which point the
titrations were stopped due to peaks beginning to quickly disappear and broaden upon the
addition of Man9. This phenomenon is characteristic of intermediate exchange in which
sharp peaks at low concentrations of ligand begin to broaden with increasing
concentrations of ligand. These peaks often become undetectable and then reappear at
high ligand concentrations. Unlike W37F, when the spectra of mutant W37Y was
overlaid with the wild-type spectra, many of its peaks overlapped indicating it was more
structurally sound (Figure 3.23). However, intermediate exchange was also detected for
mutant W37Y. After processing the spectra for the full titration, it was observed peaks
corresponding with middle titrations points (e.g. 0.6:1 and 1.2:1 Man9) had disappeared
(Figure 3.24). Neither methods used to determine the dissociation constant for slow
exchange (i.e. calculating change in peak volume) or fast exchange (i.e. calculating
change in chemical shift) were suitable methods for determining the dissociation constant
for this mutant. To accurately determine the Kd for mutant W37Y and possibly W37F, a
higher field spectrometer such as an 800 MHz instrument could be used to shift the
exchange regime to either slow or fast exchange. In comparison to wild-type Myxovirin
which exhibited slow exchange, mutant W37Y does not bind as tightly to Man9 as it
exhibits intermediate exchange.
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Figure 3.23 15N-HSQC of mutant W37Y (red) overlay on wild-type Myxovirin (black).
Structural integrity is confirmed by overlapping peaks.

Figure 3.24 Examples of residues displaying intermediate exchange with both residues
D9 and N13 missing peaks at 1.2:1 Man9:MXN (green).
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3.6 Expression and Purification of Myxovirin Antifungal Peptide Chimera
Taking advantage of Myxovirin’s ability to tolerate terminal modifications, a
lectin/antifungal peptide chimera was engineered in an attempt to create a more potent
anticryptococcal protein. Because Myxovirin likely binds to a glycoprotein in or on the
cell wall, it is proposed the lectin could be utilized to quickly deliver an AFP to its
cellular target. By fusing Myxovirin to an AFP, it is also expected the inhibitory effect of
both Myxovirin and the antifungal protein in combination would result in a more potent
protein than each of the proteins alone.
The antifungal peptide, hLF(1-11), comprising the first eleven residues
(GRRRRSVQWCA) of human lactoferrin, was chosen to add to Myxovirin’s C-terminus
because it needed no post-translational modifications (e.g. phosphorylation,
glycosylation, cyclization, etc.) to be active (Lupetti et al. 2008). This AFP was
connected to Myxovirin by a flexible linker of five Gly4Ser repeats. The length of the
linker was selected based on the estimated distance between the cryptococcal cell wall
(the location of Myxovirin’s proposed target) and the cell membrane (the location of the
AFP’s target). In the fourth repeat, a missense mutation was introduced in order to insert
a NotI restriction endonuclease site at the end of the linker. This cleavage site was
incorporated to allow for the possibility of extending the linker or replacing hLF(1-11)
with another AFP. The chimeric gene sequence was cut out of the pUC57 synthesis
vector and ligated into a pET-32c(+) expression vector. To confirm proper cloning, the
integrity of the plasmid was verified through DNA sequencing. The linear DNA
construct of the chimera is shown in Figure 3.25.
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Figure 3.25 DNA construct of MXN fused to hLF(1-11) inserted into a pET-32c(+)
vector by BglII and XhoI restriction sites. This sequence also contains both the
thioredoxin and hexahistidine tags and an additional thrombin site upstream of the 5’ end
(see Figure 2.1).

The Myxovirin chimera was expressed and purified as described previously for
antifungal assays. The lectin/AFP chimera exhibited the same level of overexpression as
wild-type Myxovirin. Overexpression of the chimeric fusion protein was visualized as
dark 24.7 kDa molecular weight bands on an SDS-PAGE gel (Figures 3.26).
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Figure 3.26 SDS-PAGE showing expression of MXN-hLF(1-11). Represented are
samples of uninduced (-) cultures and cultures induced (+) with IPTG (MW for molecular
weight ladder). The dark band indicated by the arrow designates the position and size of
the chimeric fusion protein.
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Similar to the wild-type protein, Myxovirin-hLF(1-11) was purified by metal
chelation chromatography using a nickel affinity column. Like the mutant proteins, the
chimera was almost entirely soluble and also followed the same elution profile as wildtype Myxovirin. Approximately 75% of the fusion protein was pure by visual inspection
of an SDS-PAGE gel (Figure 3.27). Analysis of the gel also showed smaller intense
bands below the Myxovirin-hLF(1-11) protein band which suggests degradation of the
chimera may have occurred after the first step purification despite the addition of
protease inhibitors to the cell lysate.

kDa
170

MW

Wash

Elution

70
40
25

MXN-hLF (1-11)

15

Figure 3.27 SDS-PAGE of FPLC Ni2+ affinity purification of MXN-hLF(1-11) fusion
protein (MW for molecular weight ladder and FT for flow-through of the loaded
supernatant). Purified MXN-hLF(1-11) fusion protein is indicated by the red arrow.

Similar to the wild-type protein, the thioredoxin/hexahistidine tag of chimera was
successfully cleaved by thrombin (Figure 3.28). The HPLC elution profile of MyxovirinhLF(1-11) exhibited less intense peaks than that of wild-type Myxovirin due to less pure
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protein collected from the previous metal chelation purification. However, the
thioredoxin/hexahistidine cleavage piece eluted at approximately the same retention time
as the wild-type protein (peak B) (Figure 3.29). Like the Myxovirin mutants, the elution
of the chimera also shifted in retention time likely due to changes in hydrophobicity and
electrostatic interactions by adding the polyglycine-serine linker and the highly basic
antifungal peptide. By SDS-PAGE gel analysis, fractions from peak A contained pure
chimeric protein (Figure 3.30). Only fractions (22-27) preceding the peak shoulder
indicative of unproperly folded protein were pooled and dialyzed.

WT MXN
kDa

MW

Uncut

Cut

MXN-hLF (1-11)
Uncut

Cut

170
70
40
25
15
10

Figure 3.28 SDS-PAGE depicting thrombin cleavage of wild-type (WT) MXN and
MXN-hLF(1-11). Pre-thrombin cleavage of each fusion protein is denoted by “Uncut”
and post-thrombin cleavage is denoted by “Cut”.
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Figure 3.29 HPLC chromatogram of MXN-hLF(1-11). Peak A is MXN-hLF(1-11) and
Peak B is remaining background protein from metal chelation chromatography along
with the thioredoxin/hexahistidine fusion protein.
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Figure 3.30 SDS-PAGE of reverse phase HPLC purification of MXN hLF(1-11).
Elution samples shown are from fractions collected from 22-27 min. (peak A in Figure
3.26).
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Purified Myxovirin-hLF(1-11) was dialyzed against MES buffer and then
lyophilized. The freeze-dried protein was resuspended in sterile PBS pH 7.4 buffer for
antifungal screening against C. neoformans. From SDS-PAGE analysis of the
resuspended chimeric protein, the protein showed no signs of degradation post HPLC
purification prior to screening.

3.7 Antifungal Activity
Wild-type Myxovirin and Myxovirin hLF(1-11) were tested at the same
concentrations for inhibitory activity against C. neoformans strain 24607. Due to
producing only a minimal amount of the chimera, the maximum concentration of each
protein tested was 40 µM (well A). Because the activity of the commercially synthesized
antifungal peptide, hLF(1-11), against the C. neoformans strain 24067 was unknown, it
was tested at a higher concentration in order to make sure its MIC could be observed.
The MIC of each agent was determined visually as the last well with no cell growth by
comparison to the positive and negative controls.
Based on the conditions of the microdilution assay, it appears both wild-type
Myxovirin and Myxovirin hLF(1-11) diminish cell growth but are not completely
inhibitory towards C. neoformans at 40 µM (Figure 3.31). Amphotericin B (AmpB)
showed antifungal activity with a MIC of 0.8 µM which is within the MIC range reported
in literature (Thompson et al. 2008). The MIC of the commercially synthesized hLF(111) was determined to be 45 µM. Since the antifungal efficacy of hLF(1-11) weakened
when fused to Myxovirin, it is postulated the flexible linker may be too short thus
limiting hLF(1-11) to reach its cellular target. To improve the chimeric protein’s
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potency, the construct will be further optimized by inserting a longer flexible linker or an
intrinsic fungal protease site to free the antifungal peptide. The lower activity against C.
neoformans observed from Myxovirin and the chimera also suggests two carbohydrate
binding domains contribute significantly to fungicidal activity.
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Figure 3.31 Microdilution testing of MXN-hLF(1-11) chimera against C. neoformans.
Well A contains the same concentration for the protein samples MXN and MXN-hLF(111). It should be noted the column for the antifungal peptide hLF(1-11) was shifted up
three wells (well D now being well A) to allow for a direct comparison to the other
protein samples at a similar concentration. From well A, each sample and control were
serially diluted two-fold down the column. The MIC is regarded as the last well with no
growth in a column. The comparison of MXN and MXN-hLF(1-11) showed no increase
in anticryptococcal activity from the chimera relative to that of native MXN as no wells
displayed fungal inhibition (i.e. no cell growth).
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CHAPTER FOUR

CONCLUSIONS & FUTURE WORK

4.1 Conclusions
Many fungal disease related deaths in the world, especially among immunocompromised individuals, are caused by the pathogenic fungi Cryptococcus neoformans.
The current antifungal drugs used to treat C. neoformans infections both trigger adverse
side effects and have begun to lose their effectiveness due to the growing challenge of
antifungal resistance. Thus, there is an imperative need for the discovery of new
anticryptococcal treatments. One such potential drug candidate is the novel antifungal
high mannose binding lectin Myxovirin, which is a homologous to the antimicrobial
lectin, Scytovirin.
In this study, seven Myxovirin mutants were structurally engineered in an effort
to improve carbohydrate affinity and in turn antifungal efficacy. All mutants were
positively verified by DNA sequencing and showed no difference in over expression
versus the wild-type protein. The mutants were also similar to the wild-type in both
solubility and elution profiles for purification via metal chelation chromatography. The
HPLC purification of the mutants showed slight variations in the elution profiles
compared to the wild-type, but this was expected due to the amino acid substitutions
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introduced. Myxovirin’s ligand, Man9, was also successfully produced through a costeffective method. The addition of another custom Sepharose N-caproylgalactosamine
affinity column allowed for more SBA to be produced in a time effective manner.
Optimization of the digestion of SBA with addition of 0.5% SDS was found to increase
the efficiency of Pronase digestion leading to a shorter digestion period. Using the
Sephacryl S-100 HR size exclusion resin resulted in a better separation of Man9 and the
other digestion products.
Through NMR chemical shift perturbation mapping, the binding of wild-type
Myxovirin to Man9 was characterized. Chemical shift perturbation mapping showed
Myxovirin exhibited slow exchange indicating tight binding to Man9. The carbohydrate
affinity of Myxovirin was determined to be 51 µM which is similar to that of Scytovirin
domain 1. Isothermal titration calorimetry suggests the interaction between the lectin and
glycan is driven enthalpically with an entropic penalty even with potential contaminants
from Man9.
Upon characterization of the Myxovirin mutants, it was found the changes
introduced to residues involved in carbohydrate binding significantly affected the
stability of the lectin. Due to some mutants exhibiting poor chemical shift dispersion and
intermediate exchange, the carbohydrate affinity was not determined for these mutants;
however, these mutants did show binding as chemical shift differences were observed
with the titration of increasing Man9. Nevertheless, when comparing to the residues in
the wild-type that exhibited slow exchange, these residues did not appear to significantly
change in the mutants. It can be concluded that Myxovirin is most stable and binds to
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Man9 best in its wild-type form and is more sensitive to structural modifications than
Scytovirin.
Finally, a Myxovirin/AFP chimera was successfully engineered, over expressed,
and established to be highly soluble. However, the addition of hLF(1-11) was found to
have an effect on protein stability and yield evidenced during the two-step purification
process. The chimeric protein did not increase anticryptococcal activity, thus the
chimeric construct needs to be re-evaluated to optimize the activity of both the lectin and
AFP.

4.2 Future Work
For further carbohydrate binding experiments, the Man9 collected from the
Sephacryl S-100 HR column can be polished by cation exchange chromatography to
reduce the potential contaminants. Because of its Asn residue, Mannose 9-GlcNAc2Asn
will weakly bind to the cation exchange column while short peptides will flow through
thus removing contamination possibly interfering with the protein ligand interaction.
Also, to better quantitate Man9, derivatization of the glycan can be performed before
PSA analysis. To create a Man9 standard for the PSA, Man9 can be derivatized with
tyrosine. The concentration of the Man9-Tyr analog can be determined by UV
spectroscopy since the molar absorptivity of Tyr is known. An absorbance conversion
factor can be acquired by analyzing a known amount of analog with the PSA and then
used to convert the absorbance of non-derivatized Man9 sample analyzed by the PSA to a
molar quantity (Anderson 2009). The Man9 glycan can also be quantified by mass
spectrometry (MS). Through the use of MS, relative quantification and structural
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confirmation of Man9 can be made by referencing signal intensities to a Man9 standard.
The derivatization technique permethylation could also be employed before analysis to
enhance ionization efficiency of the glycan (Mehta et al. 2016).
To better understand the interaction between Myxovirin and Man9, solving the
apo and carbohydrate bound structure is highly desirable. Using triple resonance
backbone sequential assignment spectra previously collected on a 500 MHz spectrometer,
over 90% of resonances have already been assigned. Also, more than half of identified
NOEs have been assigned leading to an initially calculated structure of Myxovirin (Jones
2017). However, by using an 800 MHz instrument, it is expected the remaining NOEs
can be assigned and a high-resolution structure of unbound and bound Myxovirin will be
elucidated. Determining both the structure of Myxovirin and it in complex with Man9,
will provide more information on the specificity of the lectin and will also give greater
insight into the potential mechanism by which high mannose binding lectins inhibit C.
neoformans.
It is hypothesized the current Myxovirin/AFP chimera did not augment antifungal
activity possibly due to the length of the linker limiting the movement or delivery of the
AFP to its cellular target. To test this theory, a larger flexible linker, a ten or fifteen
Gly4Ser repeat, can be inserted into the DNA construct via the NotI endonuclease site or
a protease site intrinsic to C. neoformans can be introduced at the end of linker in order to
free the AFP. Additionally, to better understand the effect Myxovirin may have on
hLF(1-11), another microdilution antifungal screening can be performed in which
Myxovirin and hLF(1-11) will be added together as two separate entities (i.e. the two
proteins no longer fused by a linker). Comparing the anticryptococcal activity of the
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combination to that of Myxovirin and hLF(1-11) alone will determine if the combination
of the two antifungals is additive, synergistic or antagonistic. To also take advantage of
two carbohydrate binding domains, a Scytovirin/AFP chimera is currently being
constructed with a different AFP, the histatin 5 fragment P113, fused to the C-terminal
end of Scytovirin.
Through conducting another BLAST search, another Scytovirin-domain like
lectin was discovered that was very similar to Myxovirin’s parent protein. This
hypothetical protein originates from Myxococcus macrosporus strain DSM 14697 whose
genome aligns with the genome of Myxococcus fulvus HW-1 by 93% (Treuner-Lange et
al. 2017). Cloning this protein and characterizing its Man9 binding will provide a better
understanding of the family of high mannose binding lectins and expand the development
of lectins as antifungal therapies.
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APPENDIX

Supporting Data

Table A.1 Site-directed mutagenesis primers for Myxovirin mutations. Mutated codons
for each forward and reverse primer are in bold.
Primer

Sequence

Y6F Forward

5’- GGTTCTGGTCCGTCATTTCGCTGGGATGAATC -3’

Y6F Reverse

5’- GATTCATCCCAGCGAAATGACGGACCAGAACC-3’

Y6W Forward

5’- GGTTCTGGTCCGTCATGGCGCTGGGATGAATC -3’

Y6W Reverse

5’- GATTCATCCCAGCGCCATGACGGACCAGAACC -3’

W8L Forward

5’- GGTCCGTCATATCGCCTGGATGAATCGCGTAA -3’

W8L Reverse

5’- TTACGCGATTCATCCAGGCGATATGACGGACC -3’

D9N Forward

5’- CCGTCATATCGCTGGAATGAATCGCGTAACCG -3’

D9N Reverse

5’- CGGTTACGCGATTCATTCCAGCGATATGACGG -3’

R12N Forward

5’- CGCTGGGATGAATCGAATAACCGTCCGGGTCC -3’

R12N Reverse

5’- GGACCCGGACGGTTATTCGATTCATCCCAGCG -3’

W37F Forward

5’- GCAGCTCTAGTGGCTTTTGTCAAGGTGAA -3’

W37F Reverse

5’- TTCACCTTGACAAAAGCCACTAGAGCTGC -3’

W37Y Forward

5’- GCAGCTCTAGTGGCTATTGTCAAGGTGAA -3’

W37Y Reverse

5’- TTCACCTTGACAATAGCCACTAGAGCTGC -3’
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